The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women with Osteoporosis
The purpose of this observational study was to investigate the effectiveness and safety of romosozumab (ROMO) and teriparatide (TPTD) in a clinical setting. 315 postmenopausal women were included based on the reimbursement criteria for ROMO and TPTD at the Department of Endocrinology at Aarhus Unive...
Gespeichert in:
| Veröffentlicht in: | The journal of clinical endocrinology and metabolism 2024-07 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | The journal of clinical endocrinology and metabolism |
| container_volume | |
| creator | Hartz, Martin C Johannessen, Fabian B Harsløf, Torben Langdahl, Bente L |
| description | The purpose of this observational study was to investigate the effectiveness and safety of romosozumab (ROMO) and teriparatide (TPTD) in a clinical setting.
315 postmenopausal women were included based on the reimbursement criteria for ROMO and TPTD at the Department of Endocrinology at Aarhus University Hospital. ROMO: Bone Mineral Density (BMD) T-score |
| doi_str_mv | 10.1210/clinem/dgae484 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3081300241</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3081300241</sourcerecordid><originalsourceid>FETCH-LOGICAL-c220t-c5fff44fdf1fa4c0906cd3d17530d9d9a014e3e34322b39ce3aaed19081720573</originalsourceid><addsrcrecordid>eNo9kE1LAzEQhoMotlavHiVHL9vma93mKKV-gFDRit6WNJnYyO5m3WSV-uuNtnoahnnmZeZB6JSSMWWUTHTlGqgn5lWBmIo9NKRS5FlBZbGPhoQwmsmCvQzQUQhvhFAhcn6IBlwSmhA2RHa5Bjy3FnR0H9BACFg1Bj8qC3GDvcUPvvbBf_W1Wv1OltC5VnUqOgPYNfjeh1hD41vVB1XhZ58a_OniGi9CBN_6zgcXjtGBVVWAk10doaer-XJ2k90trm9nl3eZZozETOfWWiGssdQqoYkkF9pwQ4ucEyONVOkD4MAFZ2zFpQauFBgqyZQWjOQFH6HzbW7b-fceQixrFzRUlWrA96HkieRJi6AJHW9RnS4MHdiy7Vytuk1JSfnjtty6LXdu08LZLrtf1WD-8T-Z_BtGCXkg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3081300241</pqid></control><display><type>article</type><title>The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women with Osteoporosis</title><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Hartz, Martin C ; Johannessen, Fabian B ; Harsløf, Torben ; Langdahl, Bente L</creator><creatorcontrib>Hartz, Martin C ; Johannessen, Fabian B ; Harsløf, Torben ; Langdahl, Bente L</creatorcontrib><description>The purpose of this observational study was to investigate the effectiveness and safety of romosozumab (ROMO) and teriparatide (TPTD) in a clinical setting.
315 postmenopausal women were included based on the reimbursement criteria for ROMO and TPTD at the Department of Endocrinology at Aarhus University Hospital. ROMO: Bone Mineral Density (BMD) T-score <-2.5 (femoral neck (FN), total hip (TH), or lumbar spine (LS)) + a fragility fracture (hip, spine, pelvis, distal forearm, or proximal humerus) within 3 years. TPTD: Within 3 years ≥2 vertebral fractures or 1 vertebral fracture + BMD T-score (FN, TH, or LS) <-3. Data was collected from medical records. The primary end point was percentage change from baseline in BMD (FN, TH, and LS) at month 12. BMD was measured by DXA.
At month 12 ROMO led to significantly (p<0.001) larger increases than TPTD in BMD (FN: 4.8% vs. 0.2%, TH: 5.7% vs. 0.3%, and LS: 13.7% vs. 9.3%). Discontinuation rate was lower with ROMO than with TPTD. Lower incidence of cardiovascular adverse events was observed with ROMO compared to TPTD. Treatment-naïve patients had non-significantly higher BMD increases compared to previously treated patients with both ROMO and TPTD.
Treatment with romosozumab yields larger increases in bone mineral density than teriparatide after 12 months and a higher rate of completion.</description><identifier>ISSN: 0021-972X</identifier><identifier>ISSN: 1945-7197</identifier><identifier>EISSN: 1945-7197</identifier><identifier>DOI: 10.1210/clinem/dgae484</identifier><identifier>PMID: 39011972</identifier><language>eng</language><publisher>United States</publisher><ispartof>The journal of clinical endocrinology and metabolism, 2024-07</ispartof><rights>The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. See the journal About page for additional terms.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c220t-c5fff44fdf1fa4c0906cd3d17530d9d9a014e3e34322b39ce3aaed19081720573</cites><orcidid>0009-0004-5535-2078 ; 0000-0002-8712-7199 ; 0009-0003-0339-0788 ; 0000-0002-8581-3523</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39011972$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hartz, Martin C</creatorcontrib><creatorcontrib>Johannessen, Fabian B</creatorcontrib><creatorcontrib>Harsløf, Torben</creatorcontrib><creatorcontrib>Langdahl, Bente L</creatorcontrib><title>The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women with Osteoporosis</title><title>The journal of clinical endocrinology and metabolism</title><addtitle>J Clin Endocrinol Metab</addtitle><description>The purpose of this observational study was to investigate the effectiveness and safety of romosozumab (ROMO) and teriparatide (TPTD) in a clinical setting.
315 postmenopausal women were included based on the reimbursement criteria for ROMO and TPTD at the Department of Endocrinology at Aarhus University Hospital. ROMO: Bone Mineral Density (BMD) T-score <-2.5 (femoral neck (FN), total hip (TH), or lumbar spine (LS)) + a fragility fracture (hip, spine, pelvis, distal forearm, or proximal humerus) within 3 years. TPTD: Within 3 years ≥2 vertebral fractures or 1 vertebral fracture + BMD T-score (FN, TH, or LS) <-3. Data was collected from medical records. The primary end point was percentage change from baseline in BMD (FN, TH, and LS) at month 12. BMD was measured by DXA.
At month 12 ROMO led to significantly (p<0.001) larger increases than TPTD in BMD (FN: 4.8% vs. 0.2%, TH: 5.7% vs. 0.3%, and LS: 13.7% vs. 9.3%). Discontinuation rate was lower with ROMO than with TPTD. Lower incidence of cardiovascular adverse events was observed with ROMO compared to TPTD. Treatment-naïve patients had non-significantly higher BMD increases compared to previously treated patients with both ROMO and TPTD.
Treatment with romosozumab yields larger increases in bone mineral density than teriparatide after 12 months and a higher rate of completion.</description><issn>0021-972X</issn><issn>1945-7197</issn><issn>1945-7197</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9kE1LAzEQhoMotlavHiVHL9vma93mKKV-gFDRit6WNJnYyO5m3WSV-uuNtnoahnnmZeZB6JSSMWWUTHTlGqgn5lWBmIo9NKRS5FlBZbGPhoQwmsmCvQzQUQhvhFAhcn6IBlwSmhA2RHa5Bjy3FnR0H9BACFg1Bj8qC3GDvcUPvvbBf_W1Wv1OltC5VnUqOgPYNfjeh1hD41vVB1XhZ58a_OniGi9CBN_6zgcXjtGBVVWAk10doaer-XJ2k90trm9nl3eZZozETOfWWiGssdQqoYkkF9pwQ4ucEyONVOkD4MAFZ2zFpQauFBgqyZQWjOQFH6HzbW7b-fceQixrFzRUlWrA96HkieRJi6AJHW9RnS4MHdiy7Vytuk1JSfnjtty6LXdu08LZLrtf1WD-8T-Z_BtGCXkg</recordid><startdate>20240716</startdate><enddate>20240716</enddate><creator>Hartz, Martin C</creator><creator>Johannessen, Fabian B</creator><creator>Harsløf, Torben</creator><creator>Langdahl, Bente L</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0004-5535-2078</orcidid><orcidid>https://orcid.org/0000-0002-8712-7199</orcidid><orcidid>https://orcid.org/0009-0003-0339-0788</orcidid><orcidid>https://orcid.org/0000-0002-8581-3523</orcidid></search><sort><creationdate>20240716</creationdate><title>The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women with Osteoporosis</title><author>Hartz, Martin C ; Johannessen, Fabian B ; Harsløf, Torben ; Langdahl, Bente L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c220t-c5fff44fdf1fa4c0906cd3d17530d9d9a014e3e34322b39ce3aaed19081720573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hartz, Martin C</creatorcontrib><creatorcontrib>Johannessen, Fabian B</creatorcontrib><creatorcontrib>Harsløf, Torben</creatorcontrib><creatorcontrib>Langdahl, Bente L</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of clinical endocrinology and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hartz, Martin C</au><au>Johannessen, Fabian B</au><au>Harsløf, Torben</au><au>Langdahl, Bente L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women with Osteoporosis</atitle><jtitle>The journal of clinical endocrinology and metabolism</jtitle><addtitle>J Clin Endocrinol Metab</addtitle><date>2024-07-16</date><risdate>2024</risdate><issn>0021-972X</issn><issn>1945-7197</issn><eissn>1945-7197</eissn><abstract>The purpose of this observational study was to investigate the effectiveness and safety of romosozumab (ROMO) and teriparatide (TPTD) in a clinical setting.
315 postmenopausal women were included based on the reimbursement criteria for ROMO and TPTD at the Department of Endocrinology at Aarhus University Hospital. ROMO: Bone Mineral Density (BMD) T-score <-2.5 (femoral neck (FN), total hip (TH), or lumbar spine (LS)) + a fragility fracture (hip, spine, pelvis, distal forearm, or proximal humerus) within 3 years. TPTD: Within 3 years ≥2 vertebral fractures or 1 vertebral fracture + BMD T-score (FN, TH, or LS) <-3. Data was collected from medical records. The primary end point was percentage change from baseline in BMD (FN, TH, and LS) at month 12. BMD was measured by DXA.
At month 12 ROMO led to significantly (p<0.001) larger increases than TPTD in BMD (FN: 4.8% vs. 0.2%, TH: 5.7% vs. 0.3%, and LS: 13.7% vs. 9.3%). Discontinuation rate was lower with ROMO than with TPTD. Lower incidence of cardiovascular adverse events was observed with ROMO compared to TPTD. Treatment-naïve patients had non-significantly higher BMD increases compared to previously treated patients with both ROMO and TPTD.
Treatment with romosozumab yields larger increases in bone mineral density than teriparatide after 12 months and a higher rate of completion.</abstract><cop>United States</cop><pmid>39011972</pmid><doi>10.1210/clinem/dgae484</doi><orcidid>https://orcid.org/0009-0004-5535-2078</orcidid><orcidid>https://orcid.org/0000-0002-8712-7199</orcidid><orcidid>https://orcid.org/0009-0003-0339-0788</orcidid><orcidid>https://orcid.org/0000-0002-8581-3523</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-972X |
| ispartof | The journal of clinical endocrinology and metabolism, 2024-07 |
| issn | 0021-972X 1945-7197 1945-7197 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3081300241 |
| source | Oxford University Press Journals All Titles (1996-Current) |
| title | The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women with Osteoporosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T08%3A13%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Effectiveness%20and%20Safety%20of%20Romosozumab%20and%20Teriparatide%20in%20Postmenopausal%20Women%20with%20Osteoporosis&rft.jtitle=The%20journal%20of%20clinical%20endocrinology%20and%20metabolism&rft.au=Hartz,%20Martin%20C&rft.date=2024-07-16&rft.issn=0021-972X&rft.eissn=1945-7197&rft_id=info:doi/10.1210/clinem/dgae484&rft_dat=%3Cproquest_cross%3E3081300241%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3081300241&rft_id=info:pmid/39011972&rfr_iscdi=true |